29 research outputs found
The Role of RANK-Ligand Inhibition in Cancer: The Story of Denosumab
The bone is a very common site of metastasis in patients with advanced cancer. Skeletal metastases are most common in breast and prostate cancer, but virtually any advanced cancer may disseminate to the bone. On the basis of recent advances in the understanding of bone remodeling processes, denosumab, a fully human monoclonal antibody against RANK-L, has been developed. Phase III clinical trials have demonstrated that denosumab is well tolerated and effective in the treatment of bone loss and prevention of skeletal-related events in patients with bone metastases
Analysis of micronucleated cells by flow cytometry. 2. Evaluating the accuracy of high-speed scoring
analysis of micronucleated cells by flow cytometry. 3. Advanced technology for detecting clastogenic activity
Analysis of micronucleated cells by flow cytometry. 1. Achieving high resolution with a malaria model
Intracellular Catabolism of an Antibody Drug Conjugate with a Non-Cleavable Linker
Abstract words: 56 Introduction words: 78
Targeting the receptor activator of nuclear factor-ÎșB (RANK) ligand in prostate cancer bone metastases
Insulin peptides. XVII. Synthesis of the A chain of human (porcine) insulin and its isolation as the S-sulfonated derivative
Mutagenic activation and detoxification of benzo[a]pyrene in vitro by hepatic cytochrome P450 1A1 and phase II enzymes in three meat-producing animals
The mutagenic activation activity of hepatic microsomes from three meat-producing animals (cattle, deer and horses) was compared with those of rats as a reference species. In the Ames Salmonella typhimurium TA98 assay, the liver microsomes of all examined animals mutagenically activated benzo[a]pyrene, an ideal promutagens, in terms of production of histidine-independent revertant colonies. The microsomes of horses had the highest ability to produce revertant colonies of the examined animals under both low and high substrate concentrations. Inhibition of this mutagenic activity using α-naphthoflavone, anti-rat CYP1A1, CYP3A2 and CYP2E1 antibodies suggests that this activity was mainly because of CYP1A1 in these animals as well as in rats. The addition of co-factors for two phase II enzymes, microsomal UDP glucoronosyl transferase and cytosolic glutathione-S-transferase, reduced the production of the revertant colonies in a concentration-dependent manner. Interestingly, horses had the highest reduction rate among the examined animals, suggesting that phase II enzymes play a great role in producing a state of balance between the bioactivation and detoxification of xenobiotics in these meat-producing animals. This report is the first to investigate the mutagenic activation activity of the hepatic microsomes and the role of phase II enzymes against this activity in meat-producing animals